Abstract
Background Alterations in innate immunity are pathologically associated with and genetically implicated in Alzheimer’s disease (AD). In the whole exome sequence (WES) dataset generated by the Alzheimer’s Disease Sequencing Project (ADSP), only the previously identified p.R47H variant in the innate immunity gene, TREM2, shows study-wide association with risk of AD. Using a novel approach, we searched the ADSP WES data to identify additional immune pathway genes with deleterious variants that, like TREM2.pR47H, show strong association with AD.
Methods Using polygenic risk scores (PRS) to analyze association with AD, we evaluated deleterious variants (CADD Phred-scaled score > 20) with a minor allele count of 20 or more in 228 genes comprising an immune co-expression network containing TREM2 (CENTREM2). A significant polygenic component composed of deleterious stop-gain and non-synonymous variants was identified, and false discovery rates were determined for the variants in this component. In genes harboring a significant variant, PRS for all variants in the genes were then analyzed.
Results The PRS for the 182 deleterious variants in CENTREM2 showed significant association with AD that was driven by 142 deleterious variants (136 non-synonymous, 6 stop-gain). In the 142 variant polygenic component, four variants had significant AD risk association: TREM2.pR47H, two deleterious stop-gain variants (FCGR1A.pR92X, and LILRB1.pY331X) in novel AD genes and 1 non-synonymous variant (ATP8B4.pG395S). Remarkably, PRS for the 36 additional variants in these four genes also showed significant association with AD. The PRS for all 40 variants in the 4 genes, showed significant, replicable association with AD and 3 additional variants in this polygenic component had significant false discovery rates: ATP8B4.pR1059Q, LILRB1.pP7P, and LILRB1.pY327Y.
Conclusions Here, we identify 3 immune pathway genes (ATP8B4, LILRB1, and FCGR1A) with a variant that associates with AD. Like TREM2.pR47H, each of the variants has a minor allele frequency less than 1% and is a deleterious, protein altering variant with a strong effect that increases or decreases (LILRB1.pY331X) risk of AD. Additional variants in these genes also alter risk of AD. The variants identified here are ideally suited for studies aimed at understanding how the innate immune system may be modulated to alter risk of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Institute on Aging [U01AG046139 to NET and SGY; RF AG051504; R01AG061796 to NET]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mayo Clinic waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses of authors: Joseph S. Reddy (Reddy.Joseph{at}mayo.edu), Xue Wang (Wang.Xue{at}mayo.edu), Mariet Allen (Allen.Mariet{at}mayo.edu), Minerva M. Carrasquillo (Carrasquillo.Minerva{at}mayo.edu), Joanna M. Biernacka (Biernacka.Joanna{at}mayo.edu), Gregory D. Jenkins (Jenkins.Gregory{at}mayo.edu), Brandon J. Coombes (coombes.brandon{at}mayo.edu), Olivia Belbin (obelbin{at}santpau.cat), Todd E. Golde (tgolde{at}ufl.edu), Nilüfer Ertekin-Taner (Taner.Nilufer{at}mayo.edu), Steven G. Younkin (younkin.steven{at}mayo.edu)
Edited texted in the methods and results for clarity and added reference for CADD annotation.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- Aβ
- amyloid β protein
- AD
- Alzheimer’s disease
- ADSP
- Alzheimer’s Disease Sequencing Project
- ATP8B4
- gene encoding probable phospholipid-transporting ATPase IM
- AUC
- area-under-the-curve
- CADD
- Combined Annotation Dependent Depletion
- CENTREM2
- co-expression network containing TREM2
- CPS
- Combined Annotation Dependent Depletion Phred-scaled score
- FCGR1A
- gene encoding Fc gamma receptor 1A
- LILRB1
- gene encoding leukocyte immunoglobulin-like receptor subfamily B member 1
- MAC
- minor allele count
- MAF
- minor allele frequency
- PC
- principal component
- PRS
- polygenic risk score
- QC
- quality control
- ROC
- receiver operator characteristics
- SE
- standard error
- TREM2
- gene encoding triggering receptor expressed on myeloid cells 2
- WES
- whole exome sequence
- WGCNA
- weighted gene co-expression network analysis.
